La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Ayr Wellness Performance dei guadagni passati
Il passato criteri di controllo 0/6
Ayr Wellness's earnings have been declining at an average annual rate of -12.6%, while the Pharmaceuticals industry saw earnings growing at 48.2% annually. Revenues have been growing at an average rate of 34.9% per year.
Informazioni chiave
-12.6%
Tasso di crescita degli utili
62.7%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 23.1% |
| Tasso di crescita dei ricavi | 34.9% |
| Rendimento del capitale proprio | -34.5% |
| Margine netto | -41.1% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Does Ayr Wellness (CSE:AYR.A) Have A Healthy Balance Sheet?
Jul 17
Ayr Wellness Inc.'s (CSE:AYR.A) Shares Not Telling The Full Story
May 24Is Ayr Wellness Inc. (CSE:AYR.A) Worth CA$2.1 Based On Its Intrinsic Value?
Dec 22Is Ayr Wellness (CSE:AYR.A) Using Debt Sensibly?
Oct 06Ayr Wellness Inc.'s (CSE:AYR.A) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Sep 01Ayr Wellness Inc. (CSE:AYR.A) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Sep 01Is There An Opportunity With Ayr Wellness Inc.'s (CSE:AYR.A) 33% Undervaluation?
Jul 11What You Need To Know About The Ayr Wellness Inc. (CSE:AYR.A) Analyst Downgrade Today
Aug 19Does Ayr Wellness (CSE:AYR.A) Have A Healthy Balance Sheet?
Jul 23Ripartizione dei ricavi e delle spese
Come Ayr Wellness guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 465 | -191 | 160 | 0 |
| 31 Mar 24 | 464 | -183 | 165 | 0 |
| 31 Dec 23 | 464 | -86 | 178 | 0 |
| 30 Sep 23 | 463 | -190 | 203 | 0 |
| 30 Jun 23 | 457 | -206 | 215 | 0 |
| 31 Mar 23 | 440 | -211 | 216 | 0 |
| 31 Dec 22 | 421 | -207 | 213 | 0 |
| 30 Sep 22 | 419 | -51 | 195 | 0 |
| 30 Jun 22 | 406 | -21 | 182 | 0 |
| 31 Mar 22 | 399 | -6 | 169 | 0 |
| 31 Dec 21 | 358 | -17 | 144 | 0 |
| 30 Sep 21 | 294 | -42 | 113 | 0 |
| 30 Jun 21 | 243 | -38 | 90 | 0 |
| 31 Mar 21 | 180 | -27 | 75 | 0 |
| 31 Dec 20 | 155 | -25 | 72 | 0 |
| 30 Sep 20 | 140 | -41 | 77 | 0 |
| 30 Jun 20 | 126 | -16 | 82 | 0 |
| 31 Mar 20 | 109 | -42 | 71 | 0 |
| 31 Dec 19 | 75 | -164 | 49 | 0 |
| 30 Sep 19 | 43 | -191 | 31 | 0 |
| 30 Jun 19 | 11 | -242 | 11 | 0 |
| 31 Mar 19 | 0 | -209 | 3 | 0 |
Guadagni di qualità: AYR.A is currently unprofitable.
Margine di profitto in crescita: AYR.A is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: AYR.A is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Accelerare la crescita: Unable to compare AYR.A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: AYR.A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-19.4%).
Rendimento del capitale proprio
ROE elevato: AYR.A has a negative Return on Equity (-34.54%), as it is currently unprofitable.